US drug major Bristol-Myers Squibb says new study data show that Ixempra (ixabepilone) plus capecitabine resulted in a significant increase in progression-free survival in triple negative breast cancer compared to capectabine alone.
The study results, which are from a pooled analysis of approximately 2,000 patients enrolled in two Phase III clinical trials of Ixempra (046 and 048), were presented at the 2008 San Antonio Breast Cancer Symposium.
In the pooled analysis of the sub-set of 443 patients with triple negative breast cancer, data show that Ixempra plus capecitabine (191 patients) is the first combination regimen to demonstrate statistically-significant (p<0.0001) PFS compared to capecitabine (208 patients) alone.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze